Skip to main content Skip to footer
HomeHome
 
  • Accueil
  • Recherche de brevets

    Connaissances des brevets

    Accéder à nos bases de données brevets et à nos outils de recherche.

    Consulter la vue d'ensemble 

    • Vue d'ensemble
    • Informations techniques
      • Vue d'ensemble
      • Espacenet - recherche de brevets
      • Serveur de publication européen
      • Recherche EP en texte intégral
    • Informations juridiques
      • Vue d'ensemble
      • Registre européen des brevets
      • Bulletin européen des brevets
      • Plan du site de l'Identifiant européen de la jurisprudence
      • Observations de tiers
    • Informations commerciales
      • Vue d'ensemble
      • PATSTAT
      • IPscore
      • Rapports d’analyse sur les technologies
    • Données
      • Vue d'ensemble
      • Technology Intelligence Platform
      • Données liées ouvertes EP
      • Jeux de données de masse
      • Services Internet
      • Couverture, codes et statistiques
    • Plateformes technologiques
      • Vue d'ensemble
      • Le plastique en pleine mutation
      • Innovation autour de l'eau
      • Innovation spatiale
      • Des technologies pour lutter contre le cancer
      • Technologies de lutte contre les incendies
      • Technologies énergétiques propres
      • Lutte contre le coronavirus
    • Ressources utiles
      • Vue d'ensemble
      • Il s'agit de votre première visite ? Qu'est-ce que l'information brevets ?
      • Information brevets de l'Asie
      • Centres d'information brevets (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Commerce et statistiques
      • Informations relatives au brevet unitaire pour la connaissance des brevets
    Image
    Plastics in Transition

    Rapport d’analyse sur les technologies de gestion des déchets plastiques

  • Demander un brevet

    Demander un brevet

    Informations pratiques concernant les procédures de dépôt et de délivrance.

    Consulter la vue d'ensemble 

    • Vue d'ensemble
    • Voie européenne
      • Vue d'ensemble
      • Guide du brevet européen
      • Oppositions
      • Procédure orale
      • Recours
      • Brevet unitaire et juridiction unifiée du brevet
      • Validation nationale
      • Requête en extension/validation
    • Voie internationale (PCT)
      • Vue d'ensemble
      • Guide euro-PCT : procédure PCT devant l'OEB
      • Décisions et communiqués
      • Dispositions et ressources PCT
      • Requête en extension/validation
      • Programme de partenariat renforcé
      • Traitement accéléré des demandes PCT
      • Patent Prosecution Highway (PPH)
      • Formations et manifestations
    • Demandes nationales
    • Trouver un mandataire agréé
    • Services MyEPO
      • Vue d'ensemble
      • Comprendre nos services
      • Accéder aux services
      • Effectuer un dépôt
      • Intervenir sur un dossier
      • Disponibilité de services en ligne
    • Formulaires
      • Vue d'ensemble
      • Requête en examen
    • Taxes
      • Vue d'ensemble
      • Taxes européennes (CBE)
      • Taxes internationales (PCT)
      • Taxes du brevet unitaire
      • Paiements des taxes et remboursements
      • Avertissement

    up

    Découvrez comment le brevet unitaire peut améliorer votre stratégie de PI

  • Informations juridiques

    Informations juridiques

    Droit européen des brevets, Journal officiel et autres textes juridiques.

    Consulter la vue d'ensemble 

    • Vue d'ensemble
    • Textes juridiques
      • Vue d'ensemble
      • Convention sur le brevet européen
      • Journal officiel
      • Directives
      • Système d'extension/de validation
      • Accord de Londres
      • Droit national relatif à la CBE
      • Unitary patent system
      • Mesures nationales relatives au brevet unitaire
    • Pratiques juridictionnelles
      • Vue d'ensemble
      • Colloque des juges européens de brevets
    • Consultations d'utilisateurs
      • Vue d'ensemble
      • Consultations en cours
      • Consultations fermées
    • Harmonisation matérielle du droit des brevets
      • Vue d'ensemble
      • The Tegernsee process
      • Groupe B+
    • Convergence des pratiques
    • Options pour les mandataires agréés
    Image
    Law and practice scales 720x237

    Restez à jour des aspects clés de décisions choisies grâce à notre publication mensuelle "Abstracts of decisions”

  • Actualités et événements

    Actualités et événements

    Nos dernières actualités, podcasts et événements.

    Consulter la vue d'ensemble 

     

    • Vue d'ensemble
    • Actualités
    • Événements
    • Prix de l'inventeur européen
      • Vue d'ensemble
      • À propos du prix
      • Catégories et prix
      • Rencontrez les finalistes
      • Proposer un inventeur
      • European Inventor Network
      • La cérémonie 2024
    • Young Inventors Prize
      • Vue d'ensemble
      • À propos du prix
      • Appel à candidatures
      • Le jury
      • Le monde, réinventé
      • La cérémonie 2025
    • Centre de presse
      • Vue d'ensemble
      • Patent Index et statistiques
      • Recherche dans le centre de presse
      • Rappel des faits
      • Droits d'auteur
      • Contact presse
      • Demande de rappel
      • Service d'alerte par courriel
    • Coup de projecteur sur l'innovation et la protection par brevets
      • Vue d'ensemble
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Brevets et société
      • Technologies spatiales et satellitaires
      • L'avenir de la médecine
      • Science des matériaux
      • Communications mobiles
      • Brevets dans le domaine des biotechnologies
      • Patent classification
      • Technologies numériques
      • La fabrication de demain
      • Books by EPO experts
    • Podcast "Talk innovation"

    podcast

    De l’idée à l’invention : notre podcast vous présente les actualités en matière de technologies et de PI

  • Formation

    Formation

    L'Académie européenne des brevets – point d'accès pour vos formations

    Consulter la vue d'ensemble 

    • Vue d'ensemble
    • Activités de formation et parcours d'apprentissage
      • Vue d'ensemble
      • Activités de formation
      • Parcours d’apprentissage
    • EEQ et CEAB
      • Vue d'ensemble
      • EEQ – Examen européen de qualification
      • CEAB – Certificat européen d’administration des brevets
      • CSP – Programme de soutien aux candidats
    • Ressources par centre d'intérêt
      • Vue d'ensemble
      • Délivrance des brevets
      • Transfert et diffusion de technologies
      • Application des droits de brevet et contentieux en matière de brevets
    • Ressources de formation par profil
      • Vue d'ensemble
      • Entreprise et responsables PI
      • Candidats à l'EEQ et CEAB
      • Juges, juristes et parquets
      • Bureaux nationaux et autorités de PI
      • Conseils en brevets et assistants juridiques
      • Universités, centres de recherche et centre de transfert de technologie
    Image
    Patent Academy catalogue

    Un vaste éventail d’opportunités de formation dans le catalogue de l’Académie européenne des brevets

  • Découvrez-nous

    Découvrez-nous

    En savoir plus sur notre travail, nos valeurs, notre histoire et notre vision.

    Consulter la vue d'ensemble 

    • Vue d'ensemble
    • L'OEB en bref
    • Les 50 ans de la Convention sur le brevet européen
      • Vue d'ensemble
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Concours d’art collaboratif pour enfants
    • Fondements juridiques et États membres
      • Vue d'ensemble
      • Fondements juridiques
      • États membres de l'Organisation européenne des brevets
      • Etats autorisant l’extension
      • Etats autorisant la validation
    • Conseil d'administration et organes auxiliaires
      • Vue d'ensemble
      • Communiqués
      • Calendrier
      • Documentation
      • Le Conseil d'administration de l'Organisation européenne des brevets
    • Principes et stratégie
      • Vue d'ensemble
      • Mission, vision et valeurs
      • Plan stratégique 2028
      • Vers une nouvelle normalité
    • Présidence et Comité de direction
      • Vue d'ensemble
      • Président António Campinos
      • Comité consultatif de direction
    • Sustainability at the EPO
      • Vue d'ensemble
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services et activités
      • Vue d'ensemble
      • Nos services et notre structure
      • Qualité
      • Consultation de nos utilisateurs
      • Coopération européenne et internationale
      • Académie européenne des brevets
      • Économiste en chef
      • Bureau de médiation
      • Signaler des actes répréhensibles
    • Observatoire des brevets et des technologies
      • Vue d'ensemble
      • Technologies
      • Acteurs de l'innovation
      • Politique et financement
      • Outils
      • À propos de l'Observatoire
    • Achats
      • Vue d'ensemble
      • Plan d’achats prévisionnel
      • La passation de marchés avec l'OEB
      • Procédures d'achat
      • Politique d'achat durable
      • Comment s‘enregistrer pour appels à la concurrence électroniques et signatures électroniques
      • Portail des achats
      • Facturation
      • Conditions générales
      • Appels à la concurrence archivés
    • Portail de transparence
      • Vue d'ensemble
      • Généralités
      • Capital humain
      • Capital environnemental
      • Capital organisationnel
      • Capital social et relationnel
      • Capital économique
      • Gouvernance
    • Statistics and trends
      • Vue d'ensemble
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • Historique de l'OEB
      • Vue d'ensemble
      • Années 1970
      • Années 1980
      • Années 1990
      • Années 2000
      • Années 2010
      • Années 2020
    • La collection d'art de l'OEB
      • Vue d'ensemble
      • La collection
      • Let's talk about art
      • Artistes
      • Médiathèque
      • What's on
      • Publications
      • Contact
      • Espace Culture A&T 5-10
      • "Longue nuit"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Suivez les dernières tendances technologiques grâce à notre Patent Index

 
Website
cancel
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • Êtes-vous novice en matière de brevets ?
  • Êtes-vous novice en matière de brevets ?
    • Go back
    • Votre entreprise et les brevets
    • Pourquoi les brevets existent-ils ?
    • Quelle est votre grande idée ?
    • Êtes-vous prêts ?
    • Ce qui vous attend
    • Comment déposer une demande de brevet
    • Mon idée est-elle brevetable?
    • Êtes-vous le premier ?
    • Quiz sur les brevets
    • Vidéo sur le brevet unitaire
  • Recherche de brevets
    • Go back
    • Vue d'ensemble
    • Informations techniques
      • Go back
      • Vue d'ensemble
      • Espacenet - recherche de brevets
        • Go back
        • Vue d'ensemble
        • Bases de données des offices nationaux et régionaux
        • Global Patent Index (GPI)
        • Notes de version
      • Serveur de publication européen
        • Go back
        • Vue d'ensemble
        • Notes de version
        • Tableau de correspondance pour les demandes Euro-PCT
        • Fichier d’autorité EP
        • Aide
      • Recherche EP en texte intégral
    • Informations juridiques
      • Go back
      • Vue d'ensemble
      • Registre européen des brevets
        • Go back
        • Vue d'ensemble
        • Notes de version archive
        • Documentation sur le Registre
          • Go back
          • Vue d'ensemble
          • Couverture de données pour lien profonds
          • Registre fédéré
          • Événements du Registre
      • Bulletin européen des brevets
        • Go back
        • Vue d'ensemble
        • Télécharger les fichiers du Bulletin
        • Recherche dans le Bulletin EP
        • Help
      • Plan du site de l'Identifiant européen de la jurisprudence
      • Observations de tiers
    • Informations commerciales
      • Go back
      • Vue d'ensemble
      • PATSTAT
      • IPscore
        • Go back
        • Notes de version
      • Rapports d’analyse sur les technologies
    • Données
      • Go back
      • Vue d'ensemble
      • Technology Intelligence Platform
      • Données liées ouvertes EP
      • Jeux de données de masse
        • Go back
        • Vue d'ensemble
        • Manuals
        • Listages de séquences
        • Données nationales en texte intégral
        • Données du Registre européen des brevets
        • Données bibliographiques mondiale de l'OEB (DOCDB)
        • Données EP en texte intégral
        • Données mondiales de l'OEB relatives aux événements juridiques (INPADOC)
        • Données bibliographiques EP (EBD)
        • Décisions des chambres de recours de l'OEB
      • Services Internet
        • Go back
        • Vue d'ensemble
        • Services brevets ouverts (OPS)
        • Serveur de publication européen (service web)
      • Couverture, codes et statistiques
        • Go back
        • Mises à jour hebdomadaires
        • Mises à jour régulières
    • Plateformes technologiques
      • Go back
      • Le plastique en pleine mutation
        • Go back
        • Overview
        • Récupération des déchets plastiques
        • Recyclage des déchets plastiques
        • Matières plastiques de substitution
      • Vue d'ensemble
      • L'innovation dans les technologies de l'eau
        • Go back
        • Overview
        • Eau salubre
        • Protection contre l'eau
      • Innovation spatiale
        • Go back
        • Vue d'ensemble
        • Astronautique
        • Observation spatiale
      • Des technologies pour lutter contre le cancer
        • Go back
        • Vue d'ensemble
        • Prévention et détection précoce
        • Diagnostics
        • Thérapies
        • Bien-être et suivi
      • Technologies de lutte contre les incendies
        • Go back
        • Vue d'ensemble
        • Détection et prévention des incendies
        • Extinction des incendies
        • Matériel de protection
        • Technologies de restauration après incendie
      • Technologies énergétiques propres
        • Go back
        • Vue d'ensemble
        • Énergies renouvelables
        • Industries à fortes émissions de carbone
        • Stockage de l’énergie et autres technologies complémentaires
      • Lutte contre le coronavirus
        • Go back
        • Vue d'ensemble
        • Vaccins et thérapies
          • Go back
          • Overview
          • Vaccins
          • Aperçu des traitements candidats contre la Covid-19
          • Antiviral et traitement symptomatique candidats
          • Acides nucléiques et anticorps de lutte contre le coronavirus
        • Diagnostics et analyses
          • Go back
          • Vue d'ensemble
          • Diagnostics - essais basés sur une protéine ou un acide nucléique
          • Protocoles analytiques
        • Informatique
          • Go back
          • Vue d'ensemble
          • Bioinformatique
          • Informatique médicale
        • Les technologies de la nouvelle normalité
          • Go back
          • Vue d'ensemble
          • Appareils, matériel et équipements
          • Procédures, actions et activités
          • Technologies numériques
        • Les inventeurs en lutte contre le coronavirus
    • Ressources utiles
      • Go back
      • Vue d'ensemble
      • Il s'agit de votre première visite ? Qu'est-ce que l'information brevets ?
        • Go back
        • Vue d'ensemble
        • Définitions de base
        • Classification des brevets
          • Go back
          • Vue d'ensemble
          • Classification coopérative des brevets (CPC)
        • Familles de brevets
          • Go back
          • Vue d'ensemble
          • Famille de brevets simple DOCDB
          • Famille de brevets élargie INPADOC
        • À propos des événements juridiques
          • Go back
          • Vue d'ensemble
          • Système de classification INPADOC
      • Information brevets de l'Asie
        • Go back
        • Vue d'ensemble
        • China (CN)
          • Go back
          • Vue d'ensemble
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Taipei Chinois (TW)
          • Go back
          • Vue d'ensemble
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Inde (IN)
          • Go back
          • Vue d'ensemble
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japon (JP)
          • Go back
          • Vue d'ensemble
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Corée (KR)
          • Go back
          • Vue d'ensemble
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Fédération de Russie (RU)
          • Go back
          • Vue d'ensemble
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Centres d'information brevets (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Commerce et statistiques
      • Informations relatives au brevet unitaire pour la connaissance des brevets
  • Demander un brevet
    • Go back
    • Vue d'ensemble
    • Voie européenne
      • Go back
      • Vue d'ensemble
      • Guide du brevet européen
      • Oppositions
      • Procédure orale
        • Go back
        • Calendrier des procédures orales
          • Go back
          • Accès du public à la procédure de recours
          • Accès du public à la procédure d’opposition
          • Calendrier des procédures orales
          • Directives techniques
      • Recours
      • Brevet unitaire et juridiction unifiée du brevet
        • Go back
        • Brevet unitaire
          • Go back
          • Vue d'ensemble
          • Cadre juridique
          • Principales caractéristiques
          • Comment obtenir un brevet unitaire
          • Coût d'un brevet unitaire
          • Traduction et compensation
          • Date de début
          • Introductory brochures
        • Vue d'ensemble
        • Juridiction unifiée du brevet
      • National validation
      • Requête en extension/validation
    • Demandes internationales
      • Go back
      • Vue d'ensemble
      • Guide euro-PCT
      • Entrée dans la phase européenne
      • Décisions et communiqués
      • Dispositions et ressources PCT
      • Requête en extension/validation
      • Programme de partenariat renforcé
      • Traitement accéléré des demandes PCT
      • Patent Prosecution Highway (PPH)
        • Go back
        • Programme Patent Prosecution Highway (PPH) – Présentation
      • Formations et manifestations
    • Voie nationale
    • Services MyEPO
      • Go back
      • Overview
      • Comprendre nos services
        • Go back
        • Vue d'ensemble
        • Exchange data with us using an API
          • Go back
          • Notes de version
      • Accéder aux services
        • Go back
        • Vue d'ensemble
        • Notes de version
      • Effectuer un dépôt
        • Go back
        • Effectuer un dépôt
        • Que faire si nos services de dépôt en ligne sont indisponibles ?
        • Notes de version
      • Intervenir sur un dossier
        • Go back
        • Notes de version
      • Disponibilité de services en ligne
    • Taxes
      • Go back
      • Vue d'ensemble
      • Taxes européennes (CBE)
        • Go back
        • Vue d'ensemble
        • Décisions et communiqués
      • Taxes internationales (PCT)
        • Go back
        • Réduction des taxes
        • Taxes pour les demandes internationales
        • Décisions et communiqués
        • Vue d'ensemble
      • Taxes du brevet unitaire
        • Go back
        • Vue d'ensemble
        • Décisions et avis
      • Paiements des taxes et remboursements
        • Go back
        • Vue d'ensemble
        • Modes de paiement
        • Premiers pas
        • FAQs et autre documentation
        • Informations techniques concernant les paiements groupés
        • Décisions et communiqués
        • Notes de version
      • Avertissement
    • Formulaires
      • Go back
      • Requête en examen
      • Vue d'ensemble
    • Trouver un mandataire agréé
  • Informations juridiques
    • Go back
    • Vue d'ensemble
    • Textes juridiques
      • Go back
      • Vue d'ensemble
      • Convention sur le brevet européen
        • Go back
        • Vue d'ensemble
        • Archive
          • Go back
          • Vue d'ensemble
          • Documentation sur la révision de la CBE en 2000
            • Go back
            • Vue d'ensemble
            • Conférence diplomatique pour la révision de la CBE
            • Travaux préparatoires
            • Nouveau texte
            • Dispositions transitoires
            • Règlement d'exécution de la CBE 2000
            • Règlement relatif aux taxes
            • Ratifications et adhésions
          • Travaux Préparatoires CBE 1973
      • Journal officiel
      • Directives
        • Go back
        • Vue d'ensemble
        • Directives CBE
        • Directives PCT de l'OEB
        • Directives relatives au brevet unitaire
        • Cycle de révision des directives
        • Consultation results
        • Résumé des contributions des utilisateurs
        • Archive
      • Système d'extension/de validation
      • Accord de Londres
      • Droit national relatif à la CBE
        • Go back
        • Vue d'ensemble
        • Archive
      • Système du brevet unitaire
        • Go back
        • Travaux préparatoires to UP and UPC
      • Mesures nationales relatives au brevet unitaire
    • Pratiques juridictionnelles
      • Go back
      • Vue d'ensemble
      • Colloque des juges européens de brevets
    • Consultations d'utilisateurs
      • Go back
      • Vue d'ensemble
      • Consultations en cours
      • Consultations fermées
    • Harmonisation matérielle du droit des brevets
      • Go back
      • Vue d'ensemble
      • The Tegernsee process
      • Groupe B+
    • Convergence des pratiques
    • Options pour les mandataires agréés
  • Actualités et événements
    • Go back
    • Vue d'ensemble
    • Actualités
    • Événements
    • Prix de l'inventeur européen
      • Go back
      • Vue d'ensemble
      • À propos du prix
      • Catégories et prix
      • Découvrir les inventeurs
      • Proposer un inventeur
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • La cérémonie 2024
    • Young Inventors Prize
      • Go back
      • Vue d'ensemble
      • À propos du prix
      • Appel à candidatures
      • Le jury
      • The world, reimagined
      • La cérémonie 2025
    • Centre de presse
      • Go back
      • Vue d'ensemble
      • Patent Index et statistiques
      • Recherche dans le centre de presse
      • Rappel des faits
        • Go back
        • Vue d'ensemble
        • L'Office européen des brevets
        • Questions/réponses sur les brevets en lien avec le coronavirus
        • Questions/réponses sur les brevets portant sur des végétaux
      • Droits d'auteur
      • Contact presse
      • Formulaire - Demande de rappel
      • Service d'alerte par courriel
    • Coup de projecteur
      • Go back
      • Vue d'ensemble
      • Technologies liées à l'eau
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Vue d'ensemble
        • CodeFest 2024 sur l'IA générative
        • CodeFest 2023 sur les plastiques verts
      • Green tech in focus
        • Go back
        • Vue d'ensemble
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Brevets et société
      • Technologies spatiales et satellitaires
        • Go back
        • Brevets et technologies spatiales
        • Vue d'ensemble
      • L'avenir de la médecine
        • Go back
        • Vue d'ensemble
        • Technologies médicales et cancer
        • Personalised medicine
      • Science des matériaux
        • Go back
        • Vue d'ensemble
        • Nanotechnologie
      • Communications mobiles
      • Biotechnologie
        • Go back
        • Biotechnologies rouges, blanches ou vertes
        • Vue d'ensemble
        • Rôle de l’OEB
        • Inventions brevetables
        • Les inventeurs dans le domaine des biotechnologies
      • Classification
        • Go back
        • Vue d'ensemble
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Vue d'ensemble
          • External partners
          • Updates on Y02 and Y04S
      • Technologies numériques
        • Go back
        • Vue d'ensemble
        • A propos des TIC
        • Matériel et logiciel
        • Intelligence artificielle
        • Quatrième révolution industrielle
      • Fabrication additive
        • Go back
        • Vue d'ensemble
        • À propos de la FA
        • Innover avec la FA
      • Books by EPO experts
    • Podcast
  • Formation
    • Go back
    • Vue d'ensemble
    • Activités de formation et parcours d'apprentissage
      • Go back
      • Vue d'ensemble
      • Activités de formation : types et formats
      • Parcours d’apprentissage
    • EEQ et CEAB
      • Go back
      • Vue d'ensemble
      • EEQ – Examen européen de qualification
        • Go back
        • Vue d'ensemble
        • Compendium
          • Go back
          • Vue d'ensemble
          • Épreuve F
          • Épreuve A
          • Épreuve B
          • Épreuve C
          • Épreuve D
          • Examen préliminaire
        • Candidats reçus
        • Archives
      • CEAB – Certificat européen d’administration des brevets
      • CSP – Programme de soutien aux candidats
    • Ressources de formation par centre d'intérêt
      • Go back
      • Vue d'ensemble
      • Délivrance des brevets
      • Transfert et diffusion de technologies
      • Application des droits de brevet et contentieux en matière de brevets
    • Ressources de formation par profil
      • Go back
      • Vue d'ensemble
      • Enterprises et responsables IP
        • Go back
        • Vue d'ensemble
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • Études de cas : technologies à forte croissance
        • Inventor's handbook
          • Go back
          • Vue d'ensemble
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Vue d'ensemble
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Vue d'ensemble
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • Candidats à l'EEQ et CEAB
        • Go back
        • Vue d'ensemble
        • Casse-têtes sur l'épreuve F
        • Questions D quotidiennes
        • Examen européen de qualification - Guide de préparation
        • CEAB
      • Juges, juristes et parquets
        • Go back
        • Vue d'ensemble
        • Compulsory licensing in Europe
        • Compétences des juridictions européennes pour les litiges en matière de brevets
      • Offices nationaux et administrations de la PI
        • Go back
        • Vue d'ensemble
        • Parcours d'apprentissage pour les examinateurs de brevets des offices nationaux
        • Parcours d'apprentissage pour agents des formalités et assistants juridiques
      • Conseils en brevets et assistants juridiques
      • Universités, centres de recherche et Offices de Transfert Technologique
        • Go back
        • Vue d'ensemble
        • Cadre modulaire d'enseignement de la propriété intellectuelle (MIPEF)
        • Programme de stages professionnels "Pan-European Seal"
          • Go back
          • Vue d'ensemble
          • Pour les étudiants
          • Pour les universités
            • Go back
            • Vue d'ensemble
            • Ressources éducatives sur la propriété intellectuelle
            • Adhésion universitaire
          • Nos jeunes professionnel(le)s
          • Programme de développement professionnel
        • Programme de recherche académique (ARP)
          • Go back
          • Vue d'ensemble
          • Projets de recherche finalisés
          • Projets de recherche en cours
        • Kit d'enseignement sur la PI
          • Go back
          • Vue d'ensemble
          • Télécharger des modules
        • Manuel de conception de cours sur la propriété intellectuelle
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • Activités fondamentales
          • Parcours inspirants et témoignages
  • Découvrez-nous
    • Go back
    • Vue d'ensemble
    • L'OEB en bref
    • Les 50 ans de la CBE
      • Go back
      • Official celebrations
      • Vue d'ensemble
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Concours d’art collaboratif pour enfants
    • Fondements juridiques et États membres
      • Go back
      • Vue d'ensemble
      • Fondements juridiques
      • Etats membres
        • Go back
        • Vue d'ensemble
        • Etats membres selon la date d'adhésion
      • Etats autorisant l’extension
      • Etats autorisant la validation
    • Conseil d'administration et organes auxiliaires
      • Go back
      • Vue d'ensemble
      • Communiqués
        • Go back
        • 2024
        • Vue d'ensemble
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendrier
      • Documentation
        • Go back
        • Vue d'ensemble
        • Documents du Comité restreint
      • Conseil d'administration
        • Go back
        • Vue d'ensemble
        • Composition
        • Représentants
        • Règlement intérieur
        • Collège des commissaires aux comptes
        • Secrétariat
        • Organes
    • Principes et stratégie
      • Go back
      • Vue d'ensemble
      • Mission, vision et valeurs
      • Plan stratégique 2028
        • Go back
        • Levier 1 : Les personnes
        • Levier 2 : Les technologies
        • Levier 3 : Des produits et services de grande qualité
        • Levier 4 : Les partenariats
        • Levier 5 : La pérennité financière
      • Vers une nouvelle normalité
      • Protection des données et confidentialité
    • Présidence et Comité de direction
      • Go back
      • Vue d'ensemble
      • A propos du Président
      • Comité consultatif de direction
    • La pérennité à l'OEB
      • Go back
      • Overview
      • Pérennité environnementale
        • Go back
        • Overview
        • Inventions environnementales inspirantes
      • Pérennité sociale
        • Go back
        • Overview
        • Inventions sociales inspirantes
      • Gouvernance et pérennité financière
    • Achats
      • Go back
      • Vue d'ensemble
      • Plan d’achats prévisionnel
      • La passation de marchés avec l'OEB
      • Procédures d'achat
      • Publications du système d'acquisition dynamique
      • Politique d'achat durable
      • Sur appels à la concurrence électroniques
      • Facturation
      • Portail des achats
        • Go back
        • Vue d'ensemble
        • Signature électronique des contrats
      • Conditions générales
      • Appels à la concurrence archivés
    • Services et activités
      • Go back
      • Vue d'ensemble
      • Nos services et notre structure
      • Qualité
        • Go back
        • Vue d'ensemble
        • Fondements
          • Go back
          • Vue d'ensemble
          • La Convention sur le brevet européen
          • Directives relatives à l'examen
          • Notre personnel
        • Comment stimuler la qualité
          • Go back
          • Vue d'ensemble
          • État de la technique
          • Système de classification
          • Outils
          • Des procédés gages de qualité
        • Produits et services
          • Go back
          • Vue d'ensemble
          • Recherches
          • Examens
          • Oppositions
          • Amélioration continue
        • La qualité grâce au travail en réseau
          • Go back
          • Vue d'ensemble
          • Engagement des utilisateurs
          • Coopération
          • Enquêtes visant à évaluer le degré de satisfaction
          • Groupes de parties prenantes sur l'assurance de la qualité
        • Charte sur la qualité des brevets
        • Plan d'action pour la qualité
        • Quality dashboard
        • Statistiques
          • Go back
          • Vue d'ensemble
          • Recherche
          • Examen
          • Opposition
        • Gestion intégrée à l'OEB
      • Consultation de nos utilisateurs
        • Go back
        • Vue d'ensemble
        • Comité consultatif permanent auprès de l'OEB
          • Go back
          • Vue d'ensemble
          • Objectifs
          • Le SACEPO et ses groupes de travail
          • Réunions
          • Espace délégués
        • Enquêtes
          • Go back
          • Vue d'ensemble
          • Méthodologie détaillée
          • Services de recherche
          • Services d'examen, actions finales et publication
          • Services d'opposition
          • Services de Formalités
          • Service clientèle
          • Services de dépôt
          • Gestion des grands comptes
          • Site web de l'OEB
          • Archives
      • Notre charte du service clientèle
      • Coopération européenne et internationale
        • Go back
        • Vue d'ensemble
        • Coopération avec les Etats membres
          • Go back
          • Vue d'ensemble
        • Coopération bilatérale avec les États non membres
          • Go back
          • Vue d'ensemble
          • Le système de validation
          • Programme de partenariat renforcé
        • Organisations internationales, coopération tripartite et IP5
        • Coopération avec les organisations internationales en dehors du système de PI
      • Académie européenne des brevets
        • Go back
        • Vue d'ensemble
        • Partenaires
      • Économiste en chef
        • Go back
        • Vue d'ensemble
        • Études économiques
      • Bureau de l'Ombud
      • Signaler des actes répréhensibles
    • Observatoire des brevets et des technologies
      • Go back
      • Vue d'ensemble
      • Technologies
        • Go back
        • Vue d'ensemble
        • Innovation contre le cancer
        • Robotique d'assistance
        • Technologies spatiales
      • Acteurs de l'innovation
        • Go back
        • Vue d'ensemble
        • Start-ups et PME
          • Go back
          • Publications
          • Vue d'ensemble
        • Les universités de recherche et les organismes publics de recherche
      • Politique et financement
        • Go back
        • Vue d'ensemble
        • Programme de financement de l'innovation
          • Go back
          • Vue d'ensemble
          • Nos études sur le financement de l'innovation
          • Initiatives de l'OEB pour les demandeurs de brevet
          • Soutien financier pour les innovateurs en Europe
        • Brevets et normes
          • Go back
          • Vue d'ensemble
          • Publications
          • Patent standards explorer
      • Outils
        • Go back
        • Vue d'ensemble
        • Deep Tech Finder
      • À propos de l'Observatoire
        • Go back
        • Vue d'ensemble
        • Programme de travail
    • Transparency portal
      • Go back
      • Vue d'ensemble
      • Généralités
        • Go back
        • Vue d'ensemble
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Vue d'ensemble
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Capital humain
      • Capital environnemental
      • Capital organisationnel
      • Capital social et relationnel
      • Capital économique
      • Gouvernance
    • Statistics and trends
      • Go back
      • Vue d'ensemble
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • Historique
      • Go back
      • Vue d'ensemble
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Collection d'art
      • Go back
      • Vue d'ensemble
      • La collection
      • Let's talk about art
      • Artistes
      • Médiathèque
      • What's on
      • Publications
      • Contact
      • Espace Culture A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Expositions précédentes
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Longue nuit"
  • Chambres de recours
    • Go back
    • Vue d'ensemble
    • Décisions des chambres de recours
      • Go back
      • Décisions récentes
      • Vue d'ensemble
      • Sélection de décisions
    • Communications des chambres de recours
    • Procédure
    • Procédures orales
    • À propos des chambres de recours
      • Go back
      • Vue d’ensemble
      • Président des chambres de recours
      • Grande Chambre de recours
        • Go back
        • Vue d’ensemble
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Chambres de recours techniques
      • Chambre de recours juridique
      • Chambre de recours statuant en matière disciplinaire
      • Praesidium
        • Go back
        • Vue d’ensemble
    • Code de conduite
    • Plan de répartition des affaires
      • Go back
      • Vue d’ensemble
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Liste annuelle des affaires
    • Communications
    • Rapport annuel
      • Go back
      • Vue d’ensemble
    • Publications
      • Go back
      • Résumés des décisions
    • La Jurisprudence des Chambres de recours
      • Go back
      • Vue d'ensemble
      • Archive
  • Service et ressources
    • Go back
    • Vue d'ensemble
    • Mises à jour du site Internet
    • Disponibilité de services en ligne
      • Go back
      • Vue d'ensemble
    • FAQ
      • Go back
      • Vue d'ensemble
    • Publications
    • Commande
      • Go back
      • Connaissances des Brevets - Produits et Services
      • Vue d'ensemble
      • Conditions générales
        • Go back
        • Vue d'ensemble
        • Produits d'informations brevets
        • Donnés brutes
        • Services brevets ouverts (OPS)
        • Charte d'utilisation équitable
    • Notifications relatives aux procédures
    • Liens utiles
      • Go back
      • Vue d'ensemble
      • Offices des brevets des Etats membres
      • Autres offices des brevets
      • Répertoires de conseils en propriété industrielle
      • Bases de données, registres et gazettes des brevets
      • Disclaimer
    • Centre d'abonnement
      • Go back
      • Vue d'ensemble
      • S'abonner
      • Gérer ses préférences
      • Se désabonner
    • Contactez-nous
      • Go back
      • Vue d'ensemble
      • Options de dépôt
      • Localisations
    • Jours fériés
    • Glossaire
    • Flux RSS
Board of Appeals
Decisions

Recent decisions

Vue d'ensemble
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Accueil
  2. Node
  3. T 1016/10 11-04-2014
Facebook X Linkedin Email

T 1016/10 11-04-2014

Identifiant européen de la jurisprudence
ECLI:EP:BA:2014:T101610.20140411
Date de la décision
11 April 2014
Numéro de l'affaire
T 1016/10
Requête en révision de
-
Numéro de la demande
07023740.9
Classe de la CIB
A61B 3/117
A61B 3/135
Langue de la procédure
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN (C)

Téléchargement et informations complémentaires:

Décision en EN 504.9 KB
Les documents concernant la procédure de recours sont disponibles dans le Registre européen des brevets
Informations bibliographiques disponibles en:
EN
Versions
Non publié
Titre de la demande

Methods for diagnosing a neurodegenerative condition

Nom du demandeur

The General Hospital Corporation

The Brigham and Women's Hospital, Inc.

Nom de l'opposant
-
Chambre
3.2.02
Sommaire
-
Dispositions juridiques pertinentes
European Patent Convention Art 53(c)
European Patent Convention Art 52(4) 1973
European Patent Convention Art 112(1)(a)
Vienna Convention on the Law of Treaties (1969) Art 31
Mot-clé

Diagnostic method (yes)

Referral to the Enlarged Board of Appeal (no)

Exergue
-
Décisions citées
G 0001/04
G 0001/07
T 0385/86
T 0964/99
T 1197/02
T 0992/03
T 0143/04
T 1255/06
Décisions dans lesquelles la présente décision est citée
T 0853/16
T 1920/21

Summary of Facts and Submissions

I. On 26 November 2009 the Examining Division posted its decision to refuse European patent application No. 07023740.9 under Articles 53(c), 54, 84, 123(2) and 52(2)(c) EPC.

II. An appeal was lodged against this decision by the applicants by notice received on 26 January 2010, with the appeal fee being paid on the same day. The statement setting out the grounds of appeal was received on 26 March 2010.

III. By communication of 27 January 2014, the Board summoned the appellants to oral proceedings and forwarded its provisional opinion.

IV. Oral proceedings were held on 11 April 2014. The appellants requested that the decision under appeal be set aside and that a patent be granted on the basis of the main request, filed with letter dated 26 March 2010, or, in the alternative, one of the 1st to 5th auxiliary requests, filed during the oral proceedings.

V. The various requests comprise the following sets of claims:

Main request:

Independent claim 1 reads as follows:

"A non-invasive method of diagnosing an amyloidogenic disorder, or a predisposition thereto, in a mammal, said method being characterised by:

illuminating a mammalian ocular lens with an excitation light beam;

detecting light signals emitted from the supranuclear or cortical region of said lens; and

analysing said detected light signals by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorimetry to detect protein aggregates in said supranuclear or cortical region;

wherein the presence or an increase in the amount of aggregates in said region as compared with a normal control value indicates that said mammal is suffering from or is at risk of developing an amyloidogenic disorder."

Claims 2 to 18 are dependent claims, with claims 17 and 18 reading as follows:

"17. A method as claimed in claim 1, wherein said amyloidogenic disorder is selected from Alzheimer's Disease (AD), Familial AD, Sporadic AD, Creutzfeldt-Jakob disease, variant Creutzfeldt-Jakob disease, spongiform encephalopathies, a Prion disease, Parkinson's disease, Huntington's disease (and trinucleotide repeat diseases), amyotrophic lateral sclerosis, Down's Syndrome (Trisomy 21), Pick's Disease (Frontotemporal Dementia), Lewy Body Disease, Hallervorden-Spatz Disease, a synucleinopathy, neuronal intranuclear inclusion disease, a tauopathy, Pick's disease, corticobasal degeneration, hereditary frontotemporal dementia and Guam amyotrophic lateral sclerosis/parkinsonism dementia complex."

"18. A method as claimed in claim 1, wherein said amyloidogenic disorder is Alzheimer's Disease."

1st auxiliary request:

Independent claim 1 reads as follows (changes over the main request highlighted in bold and strike-through):

"A [deleted: non-invasive] method [deleted: of] useful in diagnosing an amyloidogenic disorder, or a predisposition thereto, in a mammal, said method being characterized by:

illuminating a mammalian ocular lense with an excitation light beam;

detecting light signals emitted from the supranuclear or cortical region of said lense; and

analysing said detected light signals by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorimetry to detect protein aggregates in said supranuclear or cortical region;

wherein the presence or an increase in the amount of aggregates in said region as compared with a normal control value indicates that said mammal is suffering from or is at risk of developing an amyloidogenic disorder."

Claims 2 to 14 are dependent claims. The claims corresponding to claims 17 and 18 of the main request were deleted.

2nd auxiliary request:

Independent claim 1 reads as follows (changes over the main request highlighted in bold):

"A non-invasive method of diagnosing an amyloidogenic disorder, or a predisposition thereto, in a mammal, said method being characterised by:

illuminating a mammalian ocular lens with an excitation light beam;

detecting light signals emitted from the supranuclear or cortical region of said lens;

analysing said detected light signals by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorimetry with a digital autocorrelator to yield a time autocorrelation function and analysing said autocorrelation function to determine the diffusivity of the aggregates in said region to detect protein aggregates in said supranuclear or cortical region;

comparing the amount of aggregates in said supranucleur or cortical region with the amount of aggregates in a normal control subject;

wherein the presence or an increase in the amount of aggregates in said region as compared with a normal control value indicates that said mammal is suffering from or is at risk of developing an amyloidogenic disorder."

Claims 2-14 are dependent claims. The claims corresponding to claims 17 and 18 of the main request were deleted.

3rd auxiliary request:

Independent claim 1 reads as follows (changes over the main request highlighted in bold):

"A non-invasive method of diagnosing an amyloidogenic disorder, or a predisposition thereto, in a mammal, said method being characterised by:

illuminating a mammalian ocular lens with an excitation light beam;

detecting light signals emitted from the supranuclear or cortical region of said lens; by delivering light collected by a probe to a photomultiplier tube and delivering signals to an autocorrelator linked to a computer;

analysing said detected light signals by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorimetry to detect protein aggregates in said supranuclear or cortical region;

comparing the amount of aggregates in said supranuclear or cortical region with a normal control subject;

wherein the presence or an increase in the amount of aggregates in said region as compared with a normal control value indicates that said mammal is suffering from or is at risk of developing an amyloidogenic disorder"

Claims 2 to 15 are dependent claims. The claims corresponding to claims 17 and 18 of the main request were deleted.

4th auxiliary request:

Independent claim 1 reads as follows (changes over the main request highlighted in bold and strike-through):

"1. A non-invasive method of diagnosing an amyloidogenic disorder, or a predisposition thereto, in a mammal, said method being characterised by:

illuminating a mammalian ocular lens with an excitation light beam;

detecting light signals emitted from the supranuclear or cortical region of said lens; and

analyzing [deleted: said] detected scattered light signals from the supranuclear or conical region of said lens [deleted: by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorimetry to detect protein aggregates in said supranuclear or cortical region] with a digital autocorrelator to yield a time autocorrelation function and analyzing said autocorrelation function to determine the diffusivity of the aggregates in said region

wherein the presence or an increase in the amount of aggregates in said region as compared with a normal control value indicates that said mammal is suffering from or is at risk of developing an amyloidogenic disorder."

Independent claim 10 is not the subject of this decision. Claims 2 to 9 and 11 to 14 are dependent claims. The claims corresponding to claims 17 and 18 of the main request were deleted.

5th auxiliary request:

Independent claim 1 reads as follows (changes over the main request highlighted in bold and strike-through):

"A [deleted: non-invasive] method [deleted: of] useful in diagnosing an amyloidogenic disorder, or a predisposition thereto [deleted: in a mammal], said method being characterized by:

[deleted: illuminating a mammalian ocular lens with an excitation light beam;]

[deleted: detecting light signals emitted from the supranuclear or cortical region of said lens; and]

[deleted: analysing said detected light signals by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorimetry to detect protein aggregates in said supranuclear or cortical region;]

analysing light signals which correspond to protein aggregation or accumulation or a disposition of amyloidogenic proteins or peptides in a supranuclear or cortical region of an ocular lens detected by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorometry

wherein the presence or an increase in the amount of light signals corresponding to aggregates or amyloidogenic proteins or peptides from [deleted: in] said region as compared with a normal control value indicates [deleted: that said mammal is suffering from or is at] the presence of, or the risk of developing, an amyloidogenic disorder."

Claims 2 to 14 are dependent claims. The claims corresponding to claims 17 and 18 of the main request were deleted.

VI. The appellants' arguments are summarised as follows:

Paragraph 6 of G 1/04 made it clear that the exclusion of Article 53(c) EPC had to be interpreted narrowly. The considerations in G 1/07 regarding a narrow or a broad interpretation of exclusion from patentability (cf. item 3.1 together with preceding Question 1 in G 1/07) were not pertinent to the present case since they referred to methods of treatment by surgery. The principle of a narrow interpretation of exclusion from patentability had to be applied whenever diagnostic methods were under scrutiny. As a consequence, a multi-step (diagnostic) method would have to be excluded from patentability provided that all of the preceeding steps, which were constitutive for making a diagnosis as an intellectual exercise, were performed on a living human or animal body (cf. G 1/04, items 6, 6.1 and 6.4.4). This was the logical and common sense approach. In direct contradiction with the rational and the logic principles set forth by G 1/04, the Boards in T 1197/02 and T l43/04 had, without any reason, re-interpreted G 1/04. The Boards who issued these decisions - without an appropriate basis - had been misguided by erroneously applying conclusions outlined by G 1/07. They had invented a requirement for multi-step methods, which went beyond and was even in stark contrast to G 1/04. Therefore, these decisions violated the principles as set forth by G 1/04.

In view of the fact that a narrow interpretation of the exclusion from patentability had to be applied to multi-step methods in line with G 1/04, the character and the significance of the data processing step in the context of the present invention had to be considered. In the impugned decision, data processing was allegedly not classified as being a step of the "examination phase". The Examining Division had erroneously (in line with decisions T 1197/02 and T 143/04, but violating G 1/04) interpreted the list of steps (i) to (iv) in item 5 of G 1/04 as exhaustive and therefore limiting. According to that interpretation, only steps (i) to (iv) were alleged to become relevant when applying the criterion "practised on the human or animal body", whereas any additional or intermediate steps were alleged to become dismissible. However, from item 5 of G 1/04 it became clear that the issue underlying G 1/04 was not the definition of steps (i) to (iv) but whether, for a method to be excluded from patentability under Article 53(c) EPC, only the diagnosis stricto sensu was considered when interpreting the criterion "practised on a human or animal body" or, rather, whether further technical steps involved in the method had to be considered in this regard as well. Item 6 of G 1/04 generally referred to "several method steps" and "preceding steps which are constitutive for making a diagnosis as an intellectual exercise" without any limitation to particular steps (item 6.1, first sentence). The limiting interpretation of those "preceding steps" in T l197/02 did not have any basis in G 1/04. T l197/02 could not refer to G 1/04 at all, but rather directly contradicted the basic idea underlying G 1/04. There was no doubt that data processing in the present case represented a step which was constitutive for making a diagnosis since raw signals derived from scattered light did neither allow any comparison with normalised data nor any conclusion with respect to a clinically relevant condition of a subject. The Examining Division's interpretation was based on a misunderstanding of the rationale behind G 1/04. Point 6.4.3 of G 1/04 explicitly referred to method steps which actually coincided with the data processing step according to claim 1. The step of "analysing said detected light signals by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorimetry" related to highly sophisticated optical methods, which necessarily involved the processing of a large raw signal data output detected thereby. As also evident from pages 27 and 28 of the description, the data processing was certainly not merely an operation that could be carried out "mentally", but required a complex arithmetical conversion of the raw data to an analysable data set based on advanced computer and software tools. It went far beyond the human being's capabilities to convert and analyse such raw data "mentally". The complexity of the mathematics behind the conversion of the raw data into data which could then subsequently be compared with the data set used for normalisation necessarily implied the use of a computer with a specific software program (item 6.4.3 of G 1/04). The data processing step involved in the analysis of the light signals according to claim 1 represented a preceding step of technical nature, which was not practised on the human or animal body and which was constitutive for making a diagnosis. All of the criteria established by G 1/04 were thus fulfilled by the subject-matter of claim 1. Moreover, even if the approach in T 1197/02 were followed, the data processing step would form part of step a) as defined in item 2.1 of T 1197/02 and was a step of a technical nature that was not practised on the human or animal body. Therefore, even if the logic of T 1197/02 were erroneously applied, the claim would not be excluded from patentability under Article 53(c) EPC.

Furthermore G 1/07 (point IV.2) and the underlying referring decision T 992/03 of 20 October 2006 considered the question of what constituted a diagnostic method in the context of G 1/04 and concluded that there was no need to ignore certain steps which were required in the method. From paragraph 3 of referring decision T 992/03 it became clear that all the steps being part of the claimed method were considered and none of them were ignored. The steps were, as a whole, considered to be the examination phase of a medical diagnosis.

An "amyloidogenic disorder" as mentioned in claim 1 merely represented an "intermediate finding", which, according to point 6.2.3 of G 1/04, was not to be confounded with the diagnosis for curative purposes stricto sensu. Such an intermediate finding did not permit to immediately determine the nature of a disease and to decide on a particular course of medical treatment (point 3.4.1 of T 385/86, the approach of which was confirmed in G 1/04), i.e. a therapeutic strategy. An amyloidogenic disorder could be caused by a wide range of different diseases as indicated in the description, requiring entirely different types of therapeutic treatment. Even if the amyloidogenic disorder was indicative of, for instance, Alzheimer's disease, this was not yet a final diagnosis since further examinations such as cognitive tests were necessary to arrive at the final diagnosis. Since step (iv) was thus missing, claim 1 could not fall under the exclusion clause, as also held in item 3.3 of T 1255/06. This was in line with "Schulte, Patentgesetz mit EPÜ, Kommentar, 9. Auflage, Rdnr. 78" and "Benkard, EPÜ, 2. Auflage, Rdnr. 129".

The term "useful in diagnosis" in claim 1 of the 1st auxiliary request further emphasised that the final diagnosis with the attribution of a full clinical picture was not obtained, but that the claimed method only served to support the actual finding of the diagnosis.

The amendment in claim 1 of the 2nd auxiliary request that the step of analysing was performed "with a digital autocorrelator to yield a time autocorrelation function and analysing said autocorrelation function to determine the diffusivity of the aggregates in said region" further clarified that this step involved extensive data processing and thus was of a technical nature and not performed on the human or animal body.

Claim 1 of the 2nd and the 3rd auxiliary requests explicitly included the step of "comparing the amount of aggregates in said supranuclear or cortical region with a normal control subject", which was clearly of a technical nature. By denoting the comparison step (ii) as "principally of a non-technical nature" in item 2.2 of T 1197/02, the board had severely misinterpreted the term "predominantly of a non-technical nature" in item 6.4.1 of G 1/04.

The wording "analysing light signals ... detected by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorometry" in claim 1 of the 5th auxiliary request implied the presence of a measurement step, thus being in line with the requirements of Article 123(2) EPC and overcoming the respective objection in item 3.6.3 of the impugned decision.

The appellants requested the Board to refer the following questions to the Enlarged Board of Appeal:

"1. May a claim directed to a method, which addresses the detection of a phenomenon (in the present case: aggregation of an amyloid protein in the eye lense) be classified as a diagnostic method allowing diagnosis for curative purposes stricto sensu being excluded from patentability under Art. 53(c) EPC, even even [sic] if such a method is not suitable to provide a clinical picture, which allows to be addressed by an appropriate treatment, but the results of which rather constitute intermediate findings, which do not make immediately clear the underlying clinical picture (here: large diversity of distinct amyloidogenic disorders, all of which are characterized by amyloid protein aggregation in the eye lens)?

2. If for such a method as exemplified above (here: a method of diagnosing an amyloidogenic disorder or a method useful in diagnosing an amyloidogenic disorder) patentability were denied due to its character as a diagnostic method according to Art. 53(c) EPC, does denial of patentability of such a method under Art. 53(c) EPC violate the principles set forth in G 1/04 (following T 385/86), which states that

"intermediate findings of diagnostic relevance must not be confounded with diagnosis for curative purposes stricto sensu as referred to under point 5 above, which consists in attributing the detected deviation to a particular clinical picture. It follows that a method for obtaining such results or findings does not constitute sufficient basis for denying patentability by virtue of Art. 52(4) EPC (now: Art. 53(c) EPC)"?

3. If methods according to question 1 above were excluded from patentability due to their nature as providing a particular clinical picture, would Board-of-Appeal decisions T 1197/02 and T 143/04 apply G 1/04 appropriately, if one or more technical steps (here: the step of analyzing detected light signals), which are not practiced on the human or animal body, were disregarded as "preceding steps, which are constitutive for making that diagnosis" (see Conclusion of G 1/04 under point 1(ii)) - due to their nature as "intermediate steps" (see T 1197/02 and T 143/04) as allegedly not falling within the scope of steps (i), (ii) and (iii) under point 5 of the Reasons of G 1/04 - for the assessment of whether such a method is a diagnostic method under Art. 53(c) EPC or not?

Or, must all preceding steps prior to the "diagnosis for curative purposes stricto sensu representing the deductive medical or veterinary decision phase as a purely intellectual exercise" (G 1/04, Conclusion, point 1(i)) be considered for the above assessment, irrespective of whether such steps are "intermediate steps" or not?"

The appellants argued that these questions related to points of law of fundamental importance. In particular, question 1 addressed an issue which was of general significance well beyond the present case, as it referred to a frequently occurring problem in many cases potentially affected by the exclusion clause with regard to diagnostic methods. Question 3 was also important for ensuring uniform application of the law, since an entirely new approach had been taken in T 1197/02 and T 143/02 which went far beyond G 1/04. Under Article 112 EPC, the Board's decision to refer questions to the Enlarged Board of Appeal was generally not a discretionary one, but one which merely involved a certain freedom of evaluation ("Beurteilungsspielraum").

Reasons for the Decision

1. The appeal is admissible.

2. Main request

2.1 In the Conclusion of its Opinion G 1/04 (referred to as "G 1/04" in the following) the Enlarged Board of Appeal stated inter alia that:

"1. In order that the subject-matter of a claim relating to a diagnostic method practised on the human or animal body falls under the prohibition of Article 52(4) EPC [EPC 1973, now Article 53(c) EPC], the claim is to include the features relating to:

(i) the diagnosis for curative purposes stricto sensu representing the deductive medical or veterinary decision phase as a purely intellectual exercise,

(ii) the preceding steps which are constitutive for making that diagnosis, and

(iii) the specific interactions with the human or animal body which occur when carrying those out among these preceding steps which are of a technical nature.

2. [...]

3. In a diagnostic method under Article 52(4) EPC [1973], the method steps of a technical nature belonging to the preceding steps which are constitutive for making the diagnosis for curative purposes stricto sensu must satisfy the criterion "practised on the human or animal body".

4. Article 52(4) EPC [1973] does not require a specific type and intensity of interaction with the human or animal body; a preceding step of a technical nature thus satisfies the criterion "practised on the human or animal body" if its performance implies any interaction with the human or animal body, necessitating the presence of the latter."

2.2 In point 5 of G 1/04 it is further stated that the method steps to be carried out when making a diagnosis as part of the medical treatment of humans or the veterinary treatment of animals for curative purposes include:

(i) the examination phase involving the collection of data,

(ii) the comparison of these data with standard values,

(iii) the finding of any significant deviation, i.e. a symptom, during the comparison, and

(iv) the attribution of the deviation to a particular clinical picture, i.e. the deductive medical or veterinary decision phase.

The final phase (iv) is also referred to as "the diagnosis for curative purposes stricto sensu", whereas the prior steps (i) to (iii) are termed as "preceding steps related to examination, data gathering and comparison".

The expression "preceding steps" is also used subsequently in point 5.3 (referring back to point 5) and point 6 (referring back to point 5.3). Further on in this section, terms such as "preceding steps which are constitutive for making such a diagnosis" are also used (points 6.2.2, 6.2.3, 6.2.4, 6.4.1, all of which directly or indirectly refer back to point 5). In the overall context of G 1/04, it is thus clear that steps (i) to (iii) are meant when the terms "preceding steps" or "preceding steps which are constitutive for making a diagnosis" and the like are used.

2.3 In claim 1, steps (i) to (iv) are identified as follows:

step (i), the examination phase involving the collection of data:

"illuminating a mammalian ocular lens with an excitation light beam;

detecting light signals emitted from the supranuclear or cortical region of said lens;"

step (ii), the comparison of these data with standard values:

"wherein the presence or an increase in the amount of aggregates in said region as compared with a normal control value ..." [emphasis added]

step (iii), the finding of any significant deviation, i.e. a symptom, during the comparison:

"wherein the presence or an increase in the amount of aggregates in said region as compared with a normal control value indicates that said mammal is suffering from or is at risk of developing an amyloidogenic disorder." [emphasis added]. The wording "the presence or an increase ... indicates that" goes beyond the mere comparison in step (ii) and implies that a further evaluation of the comparison is performed, i.e. ascertaining that there is a deviation from the normal control value and that it is "significant", thus being indicative of a "symptom".

step (iv), the attribution of the deviation to a particular clinical picture, i.e. the deductive medical or veterinary decision phase:

"wherein the presence or an increase in the amount of aggregates in said region as compared with a normal control value indicates that said mammal is suffering from or is at risk of developing an amyloidogenic disorder" [emphasis added].

Accordingly, claim 1 includes steps (i) to (iv), and the first condition for a method to qualify as diagnostic, falling under the exception clause of Article 53(c) EPC, as required in point 1.(i) and (ii) of the Conclusion of G 1/04 is fulfilled.

2.4 The appellants argued that the assignment of step (i) in the impugned decision (which corresponds to the analysis presented above) was incorrect and should, in addition to the steps of "illuminating ..." and "detecting ..." further include the step of "analysing said detected light signals by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorimetry to detect protein aggregates in said supranuclear or cortical region" in claim 1. There was no appropriate basis in G 1/04 for leaving out such a step. On the contrary, it was explicitly required in points 6, 6.1 and 6.4.4 that all preceding steps which were constitutive for making the diagnosis had to be taken into account. The step of "analysing ..." was undoubtedly constitutive for making the diagnosis. Ignoring additional steps which were not part of the above-mentioned steps (i) to (iii) when assessing diagnostic character, as ruled in T 1197/02 and T 143/04, went beyond and was in contrast to G 1/04. The Board does not share the appellants' view, for the following reasons.

Firstly, step (i) as defined in G 1/04 concerns the examination phase involving the collection of data. The step of "analysing said detected light signals ..." is an additional ensuing step relating to further processing of the collected data.

Secondly, the above-mentioned passages in G 1/04 referred to by the appellants are taken out of context. As mentioned above in point 2.2, steps (i) to (iii) are clearly defined in point 5 of G 1/04, and the subsequent use of the term "preceding steps [...]" in G 1/04 is to be understood as referring to these definitions. In the context of the "preceding steps", point 6 explicitly refers back to point 5.3 which itself refers back to the definition in point 5. Accordingly, the reference to "all of the preceding steps which are constitutive for making a diagnosis as an intellectual exercise" in point 6 is to be understood as relating to all of the (three) preceding steps in point 5, viz. steps (i) to (iii). The use of the wording "preceding steps ..." is also consistent in the passages that follow. Point 6.4.1 explicitly refers back to the definition in point 5. Points 6.4.2, 6.4.3 and 6.4.4 refer back to point 6.4.1. Accordingly, the additional criteria discussed in these passages (which will be dealt with below) are to be understood as relating to the preceding steps (i) to (iii). Point 6.4.4 gives a justification for the requirement that "all method steps of a technical nature" should satisfy the "on the body" criterion (see point 2.7 below), in contrast to the "broad interpretation" whereby it would suffice that only a single step fulfils this criterion. Read in isolation, this might suggest that the criterion is not limited to the "preceding steps" (i)-(iii), as suggested by the appellants, but from the (repeated) reference to point 6.4.1 at the beginning of this paragraph it becomes clear that the (potentially) technical method steps mentioned in point 6.4.1, i.e. (i) to (iii), must be meant. Points 8 (which explicitly refers back to 6, 6.2.3 and 6.4.4) and 9 (which explicitly refers back to 6.4.3) of the "Recapitulation" must be read in that context and cannot be construed to suggest a different meaning, as attempted by the appellants. The sentence in point 6.1 cited by the appellants is also taken out of context. It reads "... the text of the provision [i.e. present Article 53(c) EPC] itself already gives an indication towards a narrow interpretation in the sense that, in order to be excluded from patentability, the method is to include all steps relating to it". It is presented to explain that the broader interpretation as previously discussed in G 1/04 has no basis in the EPC, and does not at all refer to the "preceding steps". Finally, the use of the term "include" in the statement in point 5 of G 1/04 (cited above in point 2.2) that "the method steps to be carried out when making a diagnosis ... include [steps (i) to (iv)]" does not mean that any further steps need to be considered in the assessment of the diagnostic character, which is to be carried out according to the criteria detailed in the subsequent passages of G 1/04. These will be discussed below, but in the present context it is worth noting that point 1.(iii) of the Conclusion refers to "the specific interactions with the human or animal body which occur when carrying those out among these preceding steps which are of a technical nature"[emphasis added], emphasising that only these preceding steps (i) to (iii) are to be considered. This also becomes evident from the fact that the term "include" is used at the beginning of point 1 of the Conclusions ("...the claim is to include the features relating to: ..."), implying that these and only these features are to be assessed.

Finally, the Board is unable to discern from point 3 of the Interlocutory Decision T 992/03 that all the steps of the underlying method claim were considered and assigned to the examination phase of a medical diagnosis. It was simply held that the claimed method led to the acquisition of data in the form of an image or a spectroscopic signal, which thus related only to the examination phase. Since steps (ii) to (iv) were lacking, the claims were considered not to relate to diagnostic methods falling under the exception clause. Accordingly, this decision does not provide support for the appellants' view that any further steps in addition to steps (i) to (iv) need to be included when assessing the diagnostic character of a method either.

2.5 Referring to section 6 of G 1/04, the appellants pointed out that the exception clause of Article 53(c) EPC had to be interpreted narrowly with regard to diagnostic methods. The Board considers, however, that the term "narrow interpretation" is used in the specific context of this section to denote the approach taken in T 385/86, to be distinguished from the "broad interpretation" according to T 964/99. In G 1/04 it was concluded that the "broad interpretation" was not justified in case of diagnostic methods. With reference to G 1/04, it is stated in the penultimate paragraph of point 3.1 of G 1/07 that "the Enlarged Board came to its conclusion that the said exclusion was indeed to be interpreted narrowly only after a thorough investigation of the wording and the purpose of the exclusion clause concerned". This is reflected by point 6.2.4 of G 1/04, where the Enlarged Board explicitly addresses the problem that, in the event of a "narrow interpretation", the exclusion could be circumvented by missing out one of the essential features of the method. Also in point 3.1 of G 1/07, it was concluded that "no general principle of narrow interpretation of exclusions from patentability" could be derived from the Vienna Convention on the Law of Treaties, and that the provision is to be "interpreted in such a manner that it takes its effect fully and achieves the purpose for which it was designed". Point 6.2.4 of G 1/04 addresses the concern that in the event of a narrow interpretation, the exclusion could perhaps be circumvented by missing out at least one of the essential features of a diagnostic method, i.e. steps (i) to (iv) as mentioned in point 6.2.3. Likewise it should not be acceptable that the exclusion could easily be circumvented by including any further technical steps not performed "on the body" (see point 2.7 below) in addition to the preceding steps (i) to (iii), such as the step of "analysing ..." in the present case. Article 53(c) would then no longer achieve the purpose for which it was designed. This concern was also raised in point 3.1.7 of the impugned decision and is shared by the Board.

2.6 The appellants further argued that an "amyloidogenic disorder", identified as step (iv) in claim 1 as indicated above, merely represented an "intermediate finding". Consequently, and according to "Schulte, Patentgesetz mit EPÜ, Kommentar, 9. Auflage, Rdnr. 78", the claimed subject-matter did not constitute a diagnostic method falling under the exception clause. According to point 6.2.3 of G 1/04, such "intermediate findings" were not to be confounded with diagnosis for curative purposes stricto sensu. Such an intermediate finding did not make it possible to immediately determine the nature of a disease and to decide on a particular course of medical treatment (points 3.4.1 and 3.2 of T 385/86), i.e. a therapeutic strategy, since an amyloidogenic disorder could be caused by a wide range of different diseases as indicated in the description, requiring entirely different types of therapeutic treatment. Since step (iv) was thus missing, claim 1 could not fall under the exception clause, in analogy to T 1255/06. The Board does not share this view, for the following reasons.

As indicated above (point 2.1), step (iv) is defined in point 5 of G 1/04 as "the attribution of the deviation to a particular clinical picture", and this is also referred to as "the diagnosis for curative purposes stricto sensu". G 1/04 provides a detailed analysis and discussion of T 385/86, but the Enlarged Board did not include in its definition of step (iv) the above-mentioned restrictions of identifying the nature of a disease or permitting a decision on a particular course of medical treatment, as postulated in T 385/86. Instead, the much broader expression "a particular clinical picture" is used (also in points 6.2.3 and 6.2.4). The term "disease" is not at all used in G 1/04 in the context of diagnosis (it only occurs in point 6.2.1 dealing with surgery). Consequently, what is decisive when determining whether or not step (iv) is present in a claim according to G 1/04 is to ascertain if "a particular clinical picture" is attributed to the deviation determined in step (iii). The fact that step (iv) is also termed "diagnosis for curative purposes stricto sensu" in G 1/04 cannot be interpreted to the effect that something going beyond the primary definition "attribution of the deviation to a particular clinical picture" is meant. This primary definition in G 1/04 thus supersedes the previous definition developed in T 385/86. The passage in "Benkard, EPÜ, 2. Auflage, Rdnr. 129" cited by the appellants merely refers to this previous definition.

In the present case, the Board considers that an "amyloidogenic disorder", detected on the basis of the amount of [amyloid] protein aggregates present in a particular region (supranuclear or cortical) of the ocular lens, is not merely an "intermediate finding" but does indeed represent a "particular clinical picture". Moreover, as stated in paragraph [0004] of the present application, amyloidogenic disorders include a wide range of different diseases such as Alzheimer's or Parkinson's disease. These diseases are also specified in claims 17 and 18. Accordingly, an "amyloidogenic disorder" undoubtedly represents a "particular clinical picture". It follows that step (iv) is clearly present in claim 1.

2.7 According to the Conclusion of G 1/04 reproduced above under point 2.1, further criteria are to be fulfilled by the "preceding steps" in order that the subject-matter of a claim relating to a diagnostic method practised on the human or animal body falls under the exception clause:

- the claim must include the specific interactions with the human or animal body which occur when carrying those out among these preceding steps which are of a technical nature (point 1.(iii));

- the method steps of a technical nature belonging to the preceding steps which are constitutive for making the diagnosis for curative purposes stricto sensu must satisfy the criterion "practised on the human or animal body" (point 3).

- a preceding step of a technical nature thus satisfies the criterion "practised on the human or animal body" if its performance implies any interaction with the human or animal body, necessitating the presence of the latter (point 4).

Accordingly, the additional criteria to be fulfilled for the preceding steps (i) to (iii) are that, if they are of a technical nature (referred to hereinafter as the "technicality criterion"), then they must also be practised on the human or animal body, in specific interaction therewith ("on the body criterion"). In point 6.4.1 it is clarified that the "on the body criterion" is to be considered only in respect of method steps of a technical nature, and that it thus does not apply to the diagnosis for curative purposes stricto sensu, i.e. the deductive decision phase, which as a purely intellectual exercise cannot be practised on the human or animal body. It follows that the criteria need not be assessed with regard to step (iv). Their evaluation with regard to steps (i) to (iii) of the present case, as further elaborated and specified in section 6.4 of G 1/04, will be discussed in the following.

2.7.1 Step (i)

Step (i), the examination phase involving the collection of data, consists in "illuminating a mammalian ocular lens with an excitation light beam" and "detecting light signals emitted from the supranuclear or cortical region of said lens" in claim 1. It is clearly of a technical nature and performed on the human or animal body, necessitating the presence of the latter and implying an interaction therewith (point 6.4.2 of G 1/04). The criteria are thus fulfilled (which was not disputed by the appellants).

2.7.2 Steps (ii) and (iii)

Steps (ii) and (iii) were identified in claim 1 (see point 2.3 above) as contained in the definition "wherein the presence or an increase in the amount of aggregates in said region as compared with a normal control value indicates that ...". This definition does not comprise anything going beyond what is stated in point 6.4.1 of G 1/04, namely "in a diagnostic method, the preceding steps which are constitutive for making a diagnosis for curative purposes may, in addition to method steps of a technical nature, include method steps such as comparing data collected in the examination phase (cf. point 5 above) with standard values belonging to the common general knowledge of the person skilled in the art. These activities are predominantly of a non-technical nature and, in any event, are not normally practised on the human or animal body". From this it may be concluded that the comparison step (ii) does not fulfil the "technicality" criterion, and that the "on the body" criterion is hence of no further relevance. The use of the term "method steps such as comparing data ..." [emphasis added] "indicates that this statement may in fact also be extended to step (iii), which is defined as "the finding of any significant deviation, i.e. a symptom, during the comparison" [emphasis added] and thus anyhow interlinked with step (ii). Accordingly, steps (ii) and (iii) as assigned to claim 1 are "predominantly of a non-technical nature" and "in any event, not normally practised on the human or animal body" within the meaning of G 1/04.

Referring to point 6.4.3 of G 1/04, the appellants argued that if a preceding step is carried out by a device without involving any interaction with the human or animal body, for instance by using a specific software program, it may not be considered to satisfy the "on the body criterion". This was the case for the comparison step as defined in the last paragraph of claim 1 which involved complex data processing by a computer going far beyond common general knowledge. The Board considers, however, that complex data processing may be involved in the analysing step (which is left out of consideration in the assignment of steps as detailed above in point 2.4). With regard to step (ii), however, the Board does not accept this argument since what is defined in the last paragraph of claim 1 amounts to just a simple comparison which does not necessitate any complex computation using data-processing devices.

2.7.3 Accordingly, all the method steps of a technical nature belonging to the preceding steps which are constitutive for making the diagnosis for curative purposes stricto sensu (which in the present case are only the steps of "illuminating ..." and "detecting ... " assigned to the examination step (i)), do satisfy the criterion "practised on the human or animal body", as required in point 6.4.4 of G 1/04.

2.8 Since the subject-matter of claim 1 of the main request fulfils all the criteria of a diagnostic method practised on the human or animal body as defined in G 1/04, it falls under the exception clause of Article 53(c) EPC.

3. 1st auxiliary request

Claim 1 differs from claim 1 of the main request in that it is directed to a method useful in diagnosing an amyloidogenic disorder, instead of a method of diagnosing ... . However, the passages of the claim to which steps (i) to (iv) were assigned are identical. The content of the claim relevant for the assessment of the applicability of the exception clause has not been changed by denoting the claimed method in a slightly different way in the introductory part of the claim. Accordingly, the above-mentioned objection with respect to the main request also applies to claim 1 of this request. The appellants' argument that the term "useful in" is to indicate that only intermediate results are obtained and that a final diagnosis is not performed is not convincing in view of the fact that step (iv) still forms part of the claim. Its subject-matter also therefore falls under the exception clause of Article 53(c) EPC.

4. 2nd auxiliary request

Claim 1 differs from claim 1 of the main request in that it specifies that a digital autocorrelator is used in the step of "analysing ..." and that a further explicit step of "comparing the amount of aggregates in said supranucleur or cortical region with the amount of aggregates in a normal control subject" is added (shown in bold in point V above). Since the step of "analysing ..." does not form part of the preceding steps (i) to (iii), the amendment therein is of no relevance for the assessment of the applicability of the exception clause. The added step of "comparing ..." amounts to a mere comparison with normal control values. It does not comprise anything going beyond what is stated with respect to step (ii) in point 6.4.1 of G 1/04, i.e. it is "predominantly of a non-technical nature and ... not normally practised on the human or animal body" as explained above in point 2.7.2.

The subject-matter of claim 1 of the 2nd auxiliary request therefore also falls under the exception clause of Article 53(c) EPC.

5. 3rd auxiliary request

Claim 1 differs from claim 1 of the main request in that after the step of "detecting ..." the expression "by delivering light collected by a probe to a photomultiplier tube and delivering signals to an autocorrelator linked to a computer;" is added, and in that the step of "comparing ..." as discussed above in point 4 is inserted (highlighted in bold in point V above). The added expression does not change the assessment regarding step (i): the step is still present in the claim and fulfils the criteria of "technicality" and "on the body". With regard to the step of "comparing ...", the same consideration applies as indicated above under point 4. The subject-matter of claim 1 of the 3rd auxiliary request therefore also falls under the exception clause of Article 53(c) EPC.

6. 4th auxiliary request

Claim 1 differs from claim 1 of the main request in that the step of "analysing ..." is further modified, which is of no relevance since this step is not taken into consideration, as already stated above in point 4. Again, the passages of the claim to which steps (i) to (iv) were assigned are identical to those of the main request. The subject-matter of claim 1 of the 4th auxiliary request therefore also falls under the exception clause of Article 53(c) EPC.

7. 5th auxiliary request

Claim 1 corresponds to that of the 5th auxiliary request underlying the impugned decision. It differs from claim 1 of the main request in that

a) it is directed to a method useful in diagnosing an amyloidogenic disorder

b) the steps of "illuminating ..." and "detecting ..." are omitted

c) the step of "analysing ..." is modified into "analysing light signals which correspond to protein aggregation or accumulation or a disposition of amyloidogenic proteins or peptides in a supranuclear or cortical region of an ocular lens detected by quasi-elastic light scattering (QLS), Raman spectroscopy or fluorometry"

d) the phrase "that said mammal is suffering from" is replaced by "the presence of" in the last paragraph of the claim.

Amendment a) does not change the assessment as explained in point 3. With respect to amendment b), the appellants stated that the step of collecting data is still implicitly comprised in the step of "analysing ..." (amendment c)), in line with "Interpretation I" in point 3.6.2 of the impugned decision (thus avoiding the objection under Article 123(2) EPC raised with regard to "Interpretation II"). Accordingly, taking the appellants' statement at face value, step (i) is implicitly still present in claim 1. It fulfils the criteria of "technicality" and "on the body" (even though the term "mammal" is no longer present in the claim, it is implicit from the expression "ocular lens" that the measurement is performed "on the body"). Amendment d) does not change the finding that step (iv) is identified in "the presence of, or the risk of developing, an amyloidogenic disorder" [emphasis added], as explained supra in points 2.3 and 2.6. The subject-matter of claim 1 of the 5th auxiliary request thus falls under the exception clause of Article 53(c) EPC as well.

8. Request for referral of questions to the Enlarged Board

Under Article 112(1)(a) EPC it is for the Boards of Appeal to refer a question to the Enlarged Board of Appeal if this appears necessary for ensuring uniform application of the law or if a point of law of fundamental importance arises. According to the established jurisprudence ("Case Law of the Boards of Appeal of the EPO", 7th ed. 2013, point IV.E.9.1), such a referral is within the discretion of the board of appeal concerned.

It is also established jurisprudence of the Boards of Appeal (loc. cit., point IV.E.9.1.2.a)) that, for a referral to be admissible, an answer to the question must be necessary in order for the referring board to be able to decide on the appeal. As is clear from its reasoning above, the Board considers that none of the three questions raised by the appellants requires an answer from the Enlarged Board of Appeal for deciding the case at issue.

Issues relevant for the present decision raised by questions 1 and 2 have been dealt with in point 2.6. As detailed in this section, a requirement that it must be possible for the "particular clinical picture" to be addressed by an appropriate treatment cannot be derived from G 1/04. It was also clarified that G 1/04 did not follow T 385/86 with regard to the definition of step (iv).

Issues relevant for the present decision raised by question 3 have been dealt with in point 2.4. It was found that G 1/04 does not require that further steps other than the "preceding steps" (i), (ii) and (iii) need to be considered in the assessment of whether or not a method is diagnostic. In the present case, the Board came to conclusions similar to those in decisions T 1197/02 and T 143/04 and saw no reason to depart therefrom in applying G 1/04. There is no lack of uniformity in the application of the law that would justify a referral on this matter.

Accordingly, the Board was able to reach the present decision based on the EPC and on what was held in G 1/04, and there is no room or need for further interpretation of G 1/04 as suggested by the appellants. A referral is not necessary in order to decide the case at issue.

Therefore, the request of the appellants for referral of the three questions to the Enlarged Board of Appeal is rejected under Article 112(1)(a) EPC.

Dispositif

Order

For these reasons it is decided that:

The appeal is dismissed.

Footer - Service & support
  • Soutien
    • Mises à jour du site Internet
    • Disponibilité de services en ligne
    • FAQ
    • Publications
    • Notifications relatives aux procédures
    • Contact
    • Centre d'abonnement
    • Jours fériés
    • Glossaire
Footer - More links
  • Centre de presse
  • Emploi et carrière
  • Single Access Portal
  • Achats
  • Chambres de recours
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Adresse bibliographique
  • Conditions d’utilisation
  • Protection des données
  • Accessibilité